2026-03-31 21:16:32
GeoVax Labs Announces Warrant Inducement Transaction to Raise $863,000
Expected Stock impact: Slightly Positive
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has entered into a warrant inducement agreement with existing institutional investors to exercise existing warrants for an aggregate of 634,658 shares of common stock at a reduced exercise price of $1.36 per share. This transaction is expected to generate approximately $863,000 in gross cash proceeds for the company, which will be utilized for working capital and general corporate purposes. The new warrants issued in connection with this transaction will allow investors to purchase up to 1,269,316 shares of common stock, exercisable after obtaining necessary shareholder approvals. The closing of this transaction is anticipated to occur on April 1, 2026, subject to customary closing conditions. The company has engaged A.G.P./Alliance Global Partners as its exclusive financial advisor for this transaction, agreeing to pay a cash fee of 7% of the gross proceeds from the exercise of the existing warrants. The issuance of the new warrants is expected to enhance the company's liquidity position while providing existing investors with an opportunity to increase their stake at a favorable price. The company plans to file a registration statement for the resale of the new warrant shares within 20 days of the closing date, ensuring compliance with securities regulations. This strategic move reflects GeoVax's commitment to strengthening its financial foundation as it advances its clinical programs, including its vaccine candidates targeting infectious diseases and cancer.
